Phase 3 Clinical Trials With Primary Completion Dates in July 2017
This is a list of Phase 3 trials with primary completion dates in July 2017 for companies with a market cap less than $1B. For complete clinical trial coverage, please see our Trial Tracker tool. It includes information on all clinical trials for publicly traded companies, screenable by stock symbol, market cap, disease, completion date, and phase.
The primary completion date is the date that the final subject was examined or received an intervention for the purposes of final collection of data for the primary outcome. It provides advance notice that a company will be announcing trial results in the near future.
| Symbol | Company | Primary Completion Date | Phase | NCT ID | Title |
|---|---|---|---|---|---|
| ACRX | AcelRx Pharmaceuticals, Inc. | 2017-07-01 | Phase 3 | NCT02662764 | Study to Evaluate the Overall Performance of the Zalviso System⢠(Sufentanil Sublingual Tablet System) 15 mcg |
| ALNY | Alnylam Pharmaceuticals, Inc. | 2017-07-01 | Phase 3 | NCT01960348 | APOLLO: The Study of an Investigational Drug, Patisiran (ALN-TTR02), for the Treatment of Transthyretin (TTR)-Mediated Amyloidosis |
| CLSD | Clearside Biomedical, Inc. | 2017-07-01 | Phase 3 | NCT02595398 | Suprachoroidal Injection of CLS-TA in Subjects With Macular Edema Associated With Non-infectious Uveitis |
| CPRX | Catalyst Pharmaceuticals, Inc. | 2017-07-01 | Phase 3 | NCT02970162 | Phase 3 Study to Evaluate Efficacy of Amifampridine Phosphate in Lambert-Eaton Myasthenic Syndrome (LEMS) |
| CYTK | Cytokinetics, Incorporated | 2017-07-01 | Phase 3 | NCT02496767 | Ventilatory Investigation of Tirasemtiv and Assessment of Longitudinal Indices After Treatment for a Year |
| EGLT | Egalet Corporation | 2017-07-01 | Phase 3 | NCT02603705 | Safety and Tolerability of Egalet-002 in Patients With Moderate-to-Severe Chronic Noncancer Pain |
| FGEN | FibroGen, Inc | 2017-07-01 | Phase 3 | NCT02021318 | Roxadustat in the Treatment of Anemia in Chronic Kidney Disease (CKD) Patients, Not on Dialysis, in Comparison to Darbepoetin Alfa |
| FOLD | Amicus Therapeutics, Inc. | 2017-07-01 | Phase 3 | NCT02384460 | ESSENCE Study: Efficacy and Safety of SD-101 Cream in Patients With Epidermolysis Bullosa |
| GKOS | Glaukos Corporation | 2017-07-01 | Phase 3 | NCT01461291 | Multicenter Study Using Glaukos® Trabecular Micro-Bypass Stent Model GTS400 Using the G2-M-IS Injector System in Conjunction With Cataract Surgery |
| MESO | Mesoblast Limited | 2017-07-01 | Phase 3 | NCT01233960 | Evaluation of PROCHYMAL® for Treatment-refractory Moderate-to-severe Crohn's Disease |
| OTIC | Otonomy, Inc. | 2017-07-01 | Phase 3 | NCT02717442 | Study of OTO-104 in Subjects With Unilateral Meniere's Disease |
| OTIC | Otonomy, Inc. | 2017-07-01 | Phase 3 | NCT02612337 | Study of OTO-104 in Subjects With Unilateral Meniere's Disease |
| PCRX | Pacira Pharmaceuticals, Inc. | 2017-07-01 | Phase 3 | NCT02713230 | Efficacy, Safety, and Pharmacokinetics of Brachial Plexus Block With EXPAREL in Shoulder Surgery |
| PCRX | Pacira Pharmaceuticals, Inc. | 2017-07-01 | Phase 3 | NCT02713178 | Efficacy, Safety, and Pharmacokinetics of Femoral Nerve Block With EXPAREL in Total Knee Arthroplasty |
| RDHL | Redhill Biopharma Ltd. | 2017-07-01 | Phase 3 | NCT02246439 | Randomized, Placebo-Controlled, Phase 3 Trial of BEKINDA (Ondansetron 24 mg Bimodal Release Tablets) for Vomiting Due to Presumed Acute Gastroenteritis or Gastritis (The GUARD Study) |
| SCMP | Sucampo Pharmaceuticals, Inc. | 2017-07-01 | Phase 3 | NCT03097861 | Evaluation of the Bioequivalence of Sprinkle and Capsule Formulations of Lubiprostone, as Compared to Placebo |
| VRX | Valeant Pharmaceuticals International, Inc. | 2017-07-01 | Phase 3 | NCT03002571 | Efficacy and Safety of IDP-124 Lotion for the Treatment of Moderate to Severe Atopic Dermatitis in Pediatric and Adult Subjects |